Members of a key reimbursement policy panel on December 6 continued to push for the creation of separate generic price bands for both middle and lower bands under the current three price-band grouping rule as a way to address unreasonable…
HOME > BUSINESS
BUSINESS
- AstraZeneca, Hitachi to Jointly Research Pathogenesis and Prognosis of COPD
December 12, 2019
- Teribone Autoinjector Hits Shelves
December 12, 2019
- Eisai Set to Renovate Tsukuba Research Laboratories, Aims for Completion by March 2023
December 12, 2019
- Otsuka Pharmaceutical Names Executive Deputy President Inoue as New Chief
December 12, 2019
- Astellas Charging Ahead with Immuno-Oncology Initiative to Save Non-Responders: Chief
December 11, 2019
- Adcetris Posts Positive Follow-Up Data for 1st-Line Use: Takeda/Seattle Genetics
December 11, 2019
- Maruho Grabs Japan Sales Rights to Peripheral Neuropathy Drug, Near 10% Stake in Solasia
December 11, 2019
- Chugai Expanding Target Range, MOAs in Antibody Drug Discovery with Its Engineering Technologies
December 11, 2019
- 1st Patient Dosed in Japan PII for Daiichi Sankyo’s ATL Drug
December 11, 2019
- Nobelpharma’s Retympa, Senju’s Aibeta Now Available
December 11, 2019
- Healios Poised to Go into the Black with Sakigake-Designated MultiStem, Revs Up Universal Cell Biz
December 10, 2019
- Novo Joins Hands with MSD in Oral Semaglutide Promotion
December 10, 2019
- Pfizer Rolls Out Japan’s 1st Avastin Biosimilar
December 10, 2019
- Takeda Updates Failed Ninlaro Trial Results for Amyloidosis
December 10, 2019
- Ono’s BTK Inhibitor Hits ORR of 88.9% in Types of B Cell Lymphomas: Japan PII
December 10, 2019
- Alzheimer’s Disease Might Be Diagnosed by Blood Sample: Sysmex, Eisai
December 10, 2019
- Kissei’s GnRH Receptor Antagonist Shows Efficacy for Uterine Fibroids in Overseas PIII: Interim Analysis
December 10, 2019
- All-Case PMS Requirement Lifted for Xalkori: Pfizer
December 10, 2019
- Fujifilm Toyama Chemical Completes Construction of New Liposome Formulation Manufacturing Facility
December 10, 2019
- MSD, Taiho to Wind Up Keytruda Copromotion at Year-End
December 9, 2019
ページ
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…